COMMUNIQUÉS West-GlobeNewswire
-
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
14/09/2026 -
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
14/09/2026 -
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
14/09/2026 -
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
14/09/2026 -
Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
14/09/2026 -
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
14/09/2026 -
Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California
14/09/2026 -
As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers
14/09/2026 -
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
14/09/2026 -
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
14/09/2026 -
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
14/09/2026 -
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
14/09/2026 -
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
14/09/2026 -
Soleo Health Expands Atlanta Footprint With Infusion Centers In Woodstock and Fayetteville, Georgia
14/09/2026 -
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
14/09/2026 -
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
14/09/2026 -
Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
14/09/2026 -
Hop Valley Brewing Co. Makes Its Downtown Eugene Comeback with New Pub at 5th Street Public Market
14/09/2026 -
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
14/09/2026
Pages